// App-Quantinova.ai

OP0128 (2021) : INTEGRATED LABORATORY ABNORMALITY PROFILES OF UPADACITINIB WITH UP TO 4.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED IN THE SELECT PHASE 3 PROGRAM

Researchers

Presenter

  • C. Charles-Schoeman

Principal Investigators

  • J. T. Giles

  • N. Lane

  • E. Choy

  • D. Furst

  • J. Vencovsk

  • A. G. Wilson

  • G. R. Burmester

  • T. Shaw

  • Y. Song

  • H. Camp

  • N. Khan

  • J. Yee

  • I. Mcinnes

Medical Centers

  • University of California Medical Center, Rheumatology, Los Angeles, California, United States of America

  • Columbia University Lupus Center, New York, NY, United States

  • University of California, Davis, Rheumatology, Sacramento, California, United States of America

  • CREATE Centre, Cardiff University, Cardiff, United Kingdom

  • David Geffen School of Medicine, University of California, Los Angeles, Division of Rheumatology, Los Angeles, California, United States of America

  • Institute of Rheumatology, Prague, Czech Republic

  • Conway Institute, University College Dublin, Center for Arthritis Research, Dublin, Ireland

  • Charité University Medicine, Rheumatology, Berlin, Germany

  • AbbVie Inc, Immunology, Illinois, United States of America

  • University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom

Locations

  • United States

  • United Kingdom

  • Czech Republic

  • Ireland

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Creatinine

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved